Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions

Xing Pei Hao, Joseph E. Willis, Thomas G. Pretlow, Jonnagadda S Rao, Gregory T. MacLennan, Ian C. Talbot, Theresa P. Pretlow

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Abnormal expression of the fragile histidine triad (FHIT) candidate tumor suppressor gene has been observed in a variety of human tumors, but little is known about its expression during colorectal tumorigenesis. Sections of 70 aberrant crypt foci (ACF), 55 adenomas, 84 primary colorectal carcinomas, and 13 metastatic lesions were evaluated immunohistochemically for Fhit expression. All normal colonic epithelium showed a strong expression of Fhit; 44% of carcinomas showed a marked loss or absence of Fhit expression. The proportion of carcinomas with reduced expression showed an increasing trend (a) with decreasing differentiation and (b) in tumors with metastases (62%) compared with tumors without metastases (38%). The proportion of metastatic lesions (12 of 13) with reduced expression of Fhit was even greater. Although only a small proportion of ACF and adenomas showed a reduction of Fhit expression, the reduced expression of Fhit was strongly associated with the degree of dysplasia in both ACF (P = 0.0002) and adenomas (P = 0.0085). The findings of reduced expression of Fhit in a small proportion of colonic precancerous lesions and in increased proportions of primary and metastatic colorectal cancers suggest that Fhit plays a role in the development and progression of some colon carcinomas.

Original languageEnglish
Pages (from-to)18-21
Number of pages4
JournalCancer Research
Volume60
Issue number1
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Aberrant Crypt Foci
Histidine
Adenoma
Colorectal Neoplasms
Carcinoma
Neoplasm Metastasis
Neoplasms
Tumor Suppressor Genes
Colon
Carcinogenesis
Epithelium

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hao, X. P., Willis, J. E., Pretlow, T. G., Rao, J. S., MacLennan, G. T., Talbot, I. C., & Pretlow, T. P. (2000). Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Cancer Research, 60(1), 18-21.

Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. / Hao, Xing Pei; Willis, Joseph E.; Pretlow, Thomas G.; Rao, Jonnagadda S; MacLennan, Gregory T.; Talbot, Ian C.; Pretlow, Theresa P.

In: Cancer Research, Vol. 60, No. 1, 01.01.2000, p. 18-21.

Research output: Contribution to journalArticle

Hao, XP, Willis, JE, Pretlow, TG, Rao, JS, MacLennan, GT, Talbot, IC & Pretlow, TP 2000, 'Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions', Cancer Research, vol. 60, no. 1, pp. 18-21.
Hao XP, Willis JE, Pretlow TG, Rao JS, MacLennan GT, Talbot IC et al. Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Cancer Research. 2000 Jan 1;60(1):18-21.
Hao, Xing Pei ; Willis, Joseph E. ; Pretlow, Thomas G. ; Rao, Jonnagadda S ; MacLennan, Gregory T. ; Talbot, Ian C. ; Pretlow, Theresa P. / Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. In: Cancer Research. 2000 ; Vol. 60, No. 1. pp. 18-21.
@article{896b0baa74344cb1a83cdd2ccc33cb8e,
title = "Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions",
abstract = "Abnormal expression of the fragile histidine triad (FHIT) candidate tumor suppressor gene has been observed in a variety of human tumors, but little is known about its expression during colorectal tumorigenesis. Sections of 70 aberrant crypt foci (ACF), 55 adenomas, 84 primary colorectal carcinomas, and 13 metastatic lesions were evaluated immunohistochemically for Fhit expression. All normal colonic epithelium showed a strong expression of Fhit; 44{\%} of carcinomas showed a marked loss or absence of Fhit expression. The proportion of carcinomas with reduced expression showed an increasing trend (a) with decreasing differentiation and (b) in tumors with metastases (62{\%}) compared with tumors without metastases (38{\%}). The proportion of metastatic lesions (12 of 13) with reduced expression of Fhit was even greater. Although only a small proportion of ACF and adenomas showed a reduction of Fhit expression, the reduced expression of Fhit was strongly associated with the degree of dysplasia in both ACF (P = 0.0002) and adenomas (P = 0.0085). The findings of reduced expression of Fhit in a small proportion of colonic precancerous lesions and in increased proportions of primary and metastatic colorectal cancers suggest that Fhit plays a role in the development and progression of some colon carcinomas.",
author = "Hao, {Xing Pei} and Willis, {Joseph E.} and Pretlow, {Thomas G.} and Rao, {Jonnagadda S} and MacLennan, {Gregory T.} and Talbot, {Ian C.} and Pretlow, {Theresa P.}",
year = "2000",
month = "1",
day = "1",
language = "English",
volume = "60",
pages = "18--21",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions

AU - Hao, Xing Pei

AU - Willis, Joseph E.

AU - Pretlow, Thomas G.

AU - Rao, Jonnagadda S

AU - MacLennan, Gregory T.

AU - Talbot, Ian C.

AU - Pretlow, Theresa P.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Abnormal expression of the fragile histidine triad (FHIT) candidate tumor suppressor gene has been observed in a variety of human tumors, but little is known about its expression during colorectal tumorigenesis. Sections of 70 aberrant crypt foci (ACF), 55 adenomas, 84 primary colorectal carcinomas, and 13 metastatic lesions were evaluated immunohistochemically for Fhit expression. All normal colonic epithelium showed a strong expression of Fhit; 44% of carcinomas showed a marked loss or absence of Fhit expression. The proportion of carcinomas with reduced expression showed an increasing trend (a) with decreasing differentiation and (b) in tumors with metastases (62%) compared with tumors without metastases (38%). The proportion of metastatic lesions (12 of 13) with reduced expression of Fhit was even greater. Although only a small proportion of ACF and adenomas showed a reduction of Fhit expression, the reduced expression of Fhit was strongly associated with the degree of dysplasia in both ACF (P = 0.0002) and adenomas (P = 0.0085). The findings of reduced expression of Fhit in a small proportion of colonic precancerous lesions and in increased proportions of primary and metastatic colorectal cancers suggest that Fhit plays a role in the development and progression of some colon carcinomas.

AB - Abnormal expression of the fragile histidine triad (FHIT) candidate tumor suppressor gene has been observed in a variety of human tumors, but little is known about its expression during colorectal tumorigenesis. Sections of 70 aberrant crypt foci (ACF), 55 adenomas, 84 primary colorectal carcinomas, and 13 metastatic lesions were evaluated immunohistochemically for Fhit expression. All normal colonic epithelium showed a strong expression of Fhit; 44% of carcinomas showed a marked loss or absence of Fhit expression. The proportion of carcinomas with reduced expression showed an increasing trend (a) with decreasing differentiation and (b) in tumors with metastases (62%) compared with tumors without metastases (38%). The proportion of metastatic lesions (12 of 13) with reduced expression of Fhit was even greater. Although only a small proportion of ACF and adenomas showed a reduction of Fhit expression, the reduced expression of Fhit was strongly associated with the degree of dysplasia in both ACF (P = 0.0002) and adenomas (P = 0.0085). The findings of reduced expression of Fhit in a small proportion of colonic precancerous lesions and in increased proportions of primary and metastatic colorectal cancers suggest that Fhit plays a role in the development and progression of some colon carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=0002571605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0002571605&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 18

EP - 21

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 1

ER -